Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ORX.STthis companyOrexo AB	SEK 1.05	-8.03×	2.12×	40.09×	-2.18×	348.1%	-213.5%	-1334.2%	-499.2%	-26.5%	-34.8%	16.6%	1×	1.47×	-6.9×	3.7×	0.0%	3	-2.4	3	B-
CANTA.STCantargia AB (publ)	SEK 1.57	7.08×	3.91×	3.28×	4.91×	1047.8%	99.0%	48.7%	46.4%	55.3%	57.9%	14.4%	0×	-1.83×	11.37×	9.8×	0.0%	5	3.27	4	A
ENZY.STEnzymatica AB (publ)	SEK 2.35	-9.05×	3.71×	8.56×	-9.17×	-287.0%	61.5%	-96.9%	-96.3%	-41.8%	-41.7%	-8.9%	0.01×	0.69×	-42.41×	3.65×	0.0%	4	10.82	1	C-
IBT-B.STInfant Bacterial Therapeutics AB (publ)	SEK 72.80	-10.43×	6.46×	0×	-7.87×	-89.1%	0.0%	0.0%	0.0%	-61.9%	-58.8%	-10.6%	0×	2.11×	0×	2.72×	0.0%	2	-1.32	1	D+
ITECH.STI-Tech AB	SEK 63.00	18.78×	3.58×	3.71×	9.05×	172.1%	28.2%	26.5%	19.7%	19.0%	20.3%	10.3%	0×	-2.82×	47.44×	9.11×	3.3%	5	14.46	4	A-
ONCO.STOncopeptides AB (publ)	SEK 1.79	-4.37×	-18.53×	15.35×	-5.24×	-767.7%	83.0%	-317.6%	-350.9%	423.8%	-230.4%	-20.4%	-2.37×	-0.26×	-15.63×	2.63×	0.0%	3	0.46	1	D+
Peer median	—	-4.37×	3.71×	3.71×	-5.24×	-89.1%	61.5%	0.0%	0.0%	19.0%	-41.7%	-8.9%	0×	-0.26×	0×	3.65×	0.0%	4	3.27	1	—